These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 17133156)

  • 21. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of respiratory syncytial virus infection in infants and young children referred to the emergency departments for lower respiratory tract diseases in Italy.
    Medici MC; Arcangeletti MC; Merolla R; Chezzi C;
    Acta Biomed; 2004 Apr; 75(1):26-33. PubMed ID: 15315084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection.
    Bloemers BL; van Furth AM; Weijerman ME; Gemke RJ; Broers CJ; Kimpen JL; Bont L
    Pediatr Infect Dis J; 2010 Jan; 29(1):39-42. PubMed ID: 19907362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and clinical features of hospitalization because of respiratory syncytial virus lower respiratory illness among children less than two years of age in a rural Asian setting.
    Djelantik IG; Gessner BD; Soewignjo S; Steinhoff M; Sutanto A; Widjaya A; Linehan M; Moniaga V; Ingerani
    Pediatr Infect Dis J; 2003 Feb; 22(2):150-7. PubMed ID: 12586979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of respiratory syncytial virus infection and influenza with emergency admissions for respiratory disease in London: an analysis of routine surveillance data.
    Mangtani P; Hajat S; Kovats S; Wilkinson P; Armstrong B
    Clin Infect Dis; 2006 Mar; 42(5):640-6. PubMed ID: 16447109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
    Noyola DE; Zuviri-González A; Castro-García JA; Ochoa-Zavala JR
    J Infect; 2007 Feb; 54(2):180-4. PubMed ID: 16580073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
    Paes B; Cole M; Latchman A; Pinelli J
    Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
    Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations.
    Paramore LC; Mahadevia PJ; Piedra PA
    Pediatr Pulmonol; 2010 Jun; 45(6):578-84. PubMed ID: 20503283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.